ReviewMolecular cancer2024
Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.
Review in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Exosomes in bone health and disease: cellular crosstalk, systemic signaling, and AI-driven advances in regenerative therapy.Stem cell research & therapy · 2026Review
- Copper-hollow mesoporous polydopamine-polyacrylic acid nanoplatform enabling photoacoustic imaging-guided photothermal/chemodynamic therapy for osteosarcoma.RSC advances · 2026Article
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- A Dual-Responsive Versatile Nanohybrid Orchestrating Tumor Elimination and Tumor-Associated Osteolysis Restoration via Sequential Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- Development and validation of a multiparametric MRI-based radiomics nomogram for the tripartite discrimination of primary benign, primary malignant, and metastatic lumbar spinal tumors.Frontiers in oncology · 2026Article
- Preoperative differentiation of primary vs. metastatic lumbar spine tumors: development and external validation of a multiparametric MRI-based radiomics nomogram.Frontiers in oncology · 2026Article
- How Emerging Nanomaterials are Effective in Bone Regeneration?International journal of nanomedicine · 2026Review
- Application of MOFs-mediated phototherapy in cancer treatment.RSC advances · 2025Review
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- PEA15 promotes osteosarcoma progression and cisplatin resistance by modulating autophagy through the FABP3-TNF signaling axis.iScience · 2025Article
- Causal association between inflammatory markers and malignant neoplasms of bone and articular cartilage using Mendelian randomization.Discover oncology · 2025Article
- Mendelian randomization reveals contrasting effects of immune signaling molecules on bone and articular cartilage malignancies.Discover oncology · 2025Article
- SNORA58 Facilitates Radioresistance via Suppressing JNK1-Mediated Ferroptosis in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Epigenetic roles of chromatin remodeling complexes in bone biology and the pathogenesis of bone‑related disease (Review).International journal of molecular medicine · 2025Review
- PSMA-Directed Theranostics in Prostate Cancer.Biomedicines · 2025Review
- Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer.Cell & bioscience · 2025Article
- Role of vitamins in the development and treatment of osteoporosis (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant bone tumors, which are difficult to treat with current clinical strategies, originate from bone tissues and can be classified into primary and secondary types. Due to the specificity of the bone microenvironment, the results of traditional means of treating bone tumors are often unsatisfactory, so there is an urgent need to develop new treatments for malignant bone tumors. Recently, nanoparticle-based approaches have shown great potential in diagnosis and treatment. Nanoparticles (NPs) have gained significant attention due to their versatility, making them highly suitable for applications in bone tissue engineering, advanced imaging techniques, and targeted drug delivery. For diagnosis, NPs enhance imaging contrast and sensitivity by integrating targeting ligands, which significantly improve the specific recognition and localization of tumor cells for early detection. For treatment, NPs enable targeted drug delivery, increasing drug accumulation at tumor sites while reducing systemic toxicity. In conclusion, understanding bone microenvironment and using the unique properties of NPs holds great promise in improving disease management, enhancing treatment outcomes, and ultimately improving the quality of life for patients with malignant bone tumors. Further research and development will undoubtedly contribute to the advancement of personalized medicine in the field of bone oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.